A BILL 
To direct the Secretary of Health and Human Services to 
conduct a demonstration program to test providing pref-
erential treatment under the Medicare, Medicaid, and 
CHIP programs for certain drugs and biologicals manu-
factured in the United States. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘American Made Phar-
4
maceuticals Act of 2022’’. 
5
23:52 Apr 06, 2022
H7400
2 
•HR 7400 IH
SEC. 2. DEMONSTRATION PROGRAM TO TEST PROVIDING 
1
PREFERENTIAL 
TREATMENT 
UNDER 
THE 
2
MEDICARE, MEDICAID, AND CHIP PROGRAMS 
3
FOR CERTAIN DRUGS AND BIOLOGICALS 
4
MANUFACTURED IN THE UNITED STATES. 
5
Part A of title XI of the Social Security Act (42 
6
U.S.C. 1301 et seq.) is amended by inserting after section 
7
1150C the following: 
8
‘‘SEC. 1150D. DEMONSTRATION PROGRAM TO TEST PRO-
9
VIDING PREFERENTIAL TREATMENT UNDER 
10
THE MEDICARE, MEDICAID, AND CHIP PRO-
11
GRAMS 
FOR 
CERTAIN 
DRUGS 
AND 
12
BIOLOGICALS 
MANUFACTURED 
IN 
THE 
13
UNITED STATES. 
14
‘‘(a) IN GENERAL.—Not later than 1 year after the 
15
date of enactment of this section, the Secretary shall con-
16
duct a demonstration program (in this section referred to 
17
as the ‘Program’) under which U.S. manufactured drugs 
18
are given preference under titles XVIII, XIX, and XXI 
19
compared to drugs that are not U.S. manufactured drugs 
20
through the use of applicable tools. 
21
‘‘(b) SITES.—The Program shall be conducted in at 
22
least 8 States. 
23
‘‘(c) DURATION.—The Secretary shall conduct the 
24
Program for a period of not less than 7 years. 
25
‘‘(d) DEFINITIONS.—In this section: 
26
23:52 Apr 06, 2022
H7400
3 
•HR 7400 IH
‘‘(1) APPLICABLE DRUG.—The term ‘applicable 
1
drug’ means— 
2
‘‘(A) a drug that is approved and marketed 
3
under section 505(j) of the Federal Food, 
4
Drug, and Cosmetic Act; 
5
‘‘(B) a biological product that is licensed 
6
and marketed under section 351(k) of the Pub-
7
lic Health Service Act; or 
8
‘‘(C) a critical drug. 
9
‘‘(2) 
APPLICABLE
U.S.-BASED
PHARMA-
10
CEUTICAL
COMPANY.—The term ‘applicable U.S.- 
11
based pharmaceutical company’ means a manufac-
12
turer (as defined in section 1860D–14A(g)(5))— 
13
‘‘(A) that has a manufacturing location in 
14
the United States for an applicable drug; 
15
‘‘(B) beginning 3 years after the date of 
16
the implementation of the Program, for which 
17
at least 50 percent of the starter products, by 
18
weight, for the applicable drugs manufactured 
19
by manufacturer are derived from countries 
20
other than covered nations (as defined in sec-
21
tion 4871(d)(2) of title 10, United States 
22
Code); and 
23
‘‘(C) that, as determined by the Sec-
24
retary— 
25
23:52 Apr 06, 2022
H7400
4 
•HR 7400 IH
‘‘(i) maintains an appropriate level of 
1
transparency on locations of manufac-
2
turing; 
3
‘‘(ii) maintains an appropriate level of 
4
diversity in sourcing; 
5
‘‘(iii) maintains appropriate levels of 
6
inventory and emergency reserves; 
7
‘‘(iv) has in place an appropriate ac-
8
tion plan for increases in demand and for 
9
when links in the supply chain break down; 
10
and 
11
‘‘(v) meets any other characteristics 
12
the Secretary determines appropriate. 
13
‘‘(3) APPLICABLE TOOLS.—The term ‘applica-
14
ble tools’ means tools determined appropriate by the 
15
Secretary, such as— 
16
‘‘(A) preferential treatment on a for-
17
mulary; 
18
‘‘(B) providing lower cost-sharing; 
19
‘‘(C) waiving rebates under the Medicaid 
20
program under title XIX; 
21
‘‘(D) establishing a Medicare Star Rating 
22
under part D of title XVIII; or 
23
23:52 Apr 06, 2022
H7400
5 
•HR 7400 IH
‘‘(E) providing bonus payments to pro-
1
viders of services and suppliers under part B of 
2
title XVIII. 
3
‘‘(4) CRITICAL DRUG.—In this section, the term 
4
‘critical drug’ includes the following: 
5
‘‘(A) A medicine, medical countermeasure, 
6
or critical input identified on the list under sec-
7
tion 3(c) of Executive Order 13944 of August 
8
6, 2020 (85 Red. Reg 49929; relating to essen-
9
tial medicines, medical Countermeasures, and 
10
critical inputs). 
11
‘‘(B) A drug or biological that— 
12
‘‘(i) is not described in subparagraph 
13
(A); 
14
‘‘(ii) is approved and marketed under 
15
section 505(c) of the Federal Food, Drug, 
16
and Cosmetic Act or is licensed and mar-
17
keted under section 351(a) of the Public 
18
Health Service Act (or is an active phar-
19
maceutical ingredient of such a drug or bi-
20
ological); and 
21
‘‘(iii) the Secretary determines— 
22
‘‘(I) is— 
23
23:52 Apr 06, 2022
H7400
6 
•HR 7400 IH
‘‘(aa) likely to be needed for 
1
use in a public health emergency; 
2
or 
3
‘‘(bb) at high risk of short 
4
supply; and 
5
‘‘(II) has a vulnerable global sup-
6
ply chain. 
7
‘‘(5) U.S. MANUFACTURED
DRUG.—The term 
8
‘U.S. manufactured drug’ means an applicable drug 
9
that is manufactured in the United States by an ap-
10
plicable U.S.-based pharmaceutical company. 
11
‘‘(e) ANNUAL REPORT
TO CONGRESS.—Not later 
12
than 1 year after the date the Secretary implements the 
13
Program, and annually thereafter for as long as the Pro-
14
gram is being conducted, the Secretary shall submit to 
15
Congress a report on activities under the Program, to-
16
gether with recommendations for such legislation and ad-
17
ministrative action as the Secretary determines to be ap-
18
propriate. 
19
‘‘(f) WAIVERS.—The Secretary may waive such provi-
20
sions of this title and titles XVIII, XIX, and XXI as the 
21
Secretary determines necessary in order to implement the 
22
Program. 
23
‘‘(g) ADMINISTRATIVE FUNDING.—There is author-
24
ized to be appropriated to the Secretary such sums as may 
25
06:12 Apr 07, 2022
H7400
7 
•HR 7400 IH
be necessary for the administrative expenses of carrying 
1
out the Program, to remain available until expended.’’. 
2
Æ 
23:52 Apr 06, 2022
H7400
